Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
Clinical trial NCT02628951 · COMPLETED
Trial details
- NCT number
- NCT02628951
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-26
- Primary completion
- 2019-01-02
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.